# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances
0, Journal, 0, 13, "Ophthalmology", "", "<http://ctro/data#Publication_100134> <http://ctro/data#hasJournal> \"Ophthalmology\"."
1, PublicationYear, 16, 20, "2002", "", "<http://ctro/data#Publication_100134> <http://ctro/data#hasPublicationYear> \"2002\"."
2, Title, 71, 278, "Three - month comparison of brimonidine and latanoprost as adjunctive therapy in glaucoma and ocular hypertension patients uncontrolled on beta - blockers : tolerance and peak intraocular pressure lowering .", "", "<http://ctro/data#Publication_100134> <http://ctro/data#hasTitle> \"Three - month comparison of brimonidine and latanoprost as adjunctive therapy in glaucoma and ocular hypertension patients uncontrolled on beta - blockers : tolerance and peak intraocular pressure lowering .\"."
71, Duration, 71, 84, "Three - month", "", "<http://ctro/data#ClinicalTrial_100142> <http://ctro/data#hasCTduration> \"Three - month\"."
72, Brimonidine, 99, 110, "brimonidine", "", 
73, Latanoprost, 115, 126, "latanoprost", "", 
3, Glaucoma, 152, 160, "glaucoma", "", "<http://ctro/data#Glaucoma_100151> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#Glaucoma>. <http://ctro/data#ClinicalTrial_100142> <http://ctro/data#analysesHealthCondition> <http://ctro/data#Glaucoma_100151>."
4, OcularHypertension, 165, 184, "ocular hypertension", "", "<http://ctro/data#ClinicalTrial_100142> <http://ctro/data#analysesHealthCondition> <http://ctro/data#OcularHypertension>."
5, Peak_IOP, 242, 267, "peak intraocular pressure", "", 
6, Author, 279, 289, "Simmons ST", "", "<http://ctro/data#Publication_100134> <http://ctro/data#hasAuthor> \"Simmons ST\"."
7, Author, 298, 305, "Earl ML", "", "<http://ctro/data#Publication_100134> <http://ctro/data#hasAuthor> \"Earl ML\"."
136, Drug, 308, 316, "Alphagan", "", 
135, Drug, 319, 326, "Xalatan", "", 
67, USA, 433, 436, "USA", "", "<http://ctro/data#Population_100164> <http://ctro/data#hasCountry> <http://ctro/data#USA>."
8, ObjectiveDescription, 528, 746, "To compare the tolerance and peak intraocular pressure ( IOP ) - lowering efficacy of brimonidine and latanoprost as adjunctive therapy in patients with ocular hypertension or glaucoma uncontrolled on beta - blockers .", "", "<http://ctro/data#ClinicalTrial_100142> <http://ctro/data#hasObjectiveDescription> \"To compare the tolerance and peak intraocular pressure ( IOP ) - lowering efficacy of brimonidine and latanoprost as adjunctive therapy in patients with ocular hypertension or glaucoma uncontrolled on beta - blockers .\"."
9, Peak_IOP, 557, 582, "peak intraocular pressure", "", 
10, IOP, 585, 588, "IOP", "", 
74, Brimonidine, 614, 625, "brimonidine", "", 
75, Latanoprost, 630, 641, "latanoprost", "", 
11, OcularHypertension, 681, 700, "ocular hypertension", "", 
12, Glaucoma, 704, 712, "glaucoma", "", 
145, Precondition, 713, 744, "uncontrolled on beta - blockers", "", "<http://ctro/data#Population_100164> <http://ctro/data#hasPrecondition> \"uncontrolled on beta - blockers\"."
123, Prospective, 758, 769, "prospective", "", "<http://ctro/data#ClinicalTrial_100142> <http://ctro/data#hasCTDesign> <http://ctro/data#Prospective>."
13, Multicenter, 772, 783, "multicenter", "", "<http://ctro/data#ClinicalTrial_100142> <http://ctro/data#hasCTDesign> <http://ctro/data#Multicenter>."
14, DoubleBlind, 786, 801, "double - masked", "", "<http://ctro/data#ClinicalTrial_100142> <http://ctro/data#hasCTDesign> <http://ctro/data#DoubleBlind>."
15, Parallel, 804, 812, "parallel", "", "<http://ctro/data#ClinicalTrial_100142> <http://ctro/data#hasCTDesign> <http://ctro/data#Parallel>."
16, NumberPatientsCT, 854, 873, "One hundred fifteen", "", "<http://ctro/data#ClinicalTrial_100142> <http://ctro/data#hasNumberPatientsCT> \"One hundred fifteen\"."
17, IOP, 888, 891, "IOP", "", 
154, Precondition, 892, 953, "inadequately controlled on topical beta - blocker monotherapy", "", "<http://ctro/data#Population_100164> <http://ctro/data#hasPrecondition> \"inadequately controlled on topical beta - blocker monotherapy\"."
18, Randomized, 980, 988, "randomly", "", "<http://ctro/data#ClinicalTrial_100142> <http://ctro/data#hasCTDesign> <http://ctro/data#Randomized>."
155, Brimonidine, 1009, 1020, "brimonidine", "", "<http://ctro/data#Medication_100218> <http://ctro/data#hasDrug> <http://ctro/data#Brimonidine>."
19, DoseValue, 1023, 1028, "0 . 2", "", "<http://ctro/data#Medication_100218> <http://ctro/data#hasDoseValue> \"0 . 2\"."
76, Percentage, 1029, 1030, "%", "", "<http://ctro/data#Medication_100218> <http://ctro/data#hasDoseUnit> <http://ctro/data#Percentage>."
77, Frequency, 1033, 1044, "twice a day", "", "<http://ctro/data#Intervention_100206> <http://ctro/data#hasFrequency> \"twice a day\"."
78, Latanoprost, 1048, 1059, "latanoprost", "", "<http://ctro/data#Latanoprost_100226> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#Latanoprost>. <http://ctro/data#Medication_100225> <http://ctro/data#hasDrug> <http://ctro/data#Latanoprost_100226>."
20, DoseValue, 1062, 1069, "0 . 005", "", "<http://ctro/data#Medication_100225> <http://ctro/data#hasDoseValue> \"0 . 005\"."
21, Percentage, 1070, 1071, "%", "", "<http://ctro/data#Medication_100225> <http://ctro/data#hasDoseUnit> <http://ctro/data#Percentage>."
79, Frequency, 1074, 1083, "every day", "", "<http://ctro/data#Intervention_100212> <http://ctro/data#hasFrequency> \"every day\"."
80, Duration, 1110, 1118, "3 months", "", 
81, TimePoint, 1127, 1134, "1 month", "", 
69, Peak_IOP, 1216, 1227, "IOP at peak", "", 
83, Crossover, 1245, 1257, "crossed over", "", "<http://ctro/data#ClinicalTrial_100142> <http://ctro/data#hasCTDesign> <http://ctro/data#Crossover>."
22, DiffGroupAbsValue, 1376, 1377, "1", "", 
23, mmHg, 1378, 1382, "mmHg", "", 
24, Mean, 1386, 1390, "mean", "", 
25, IOP, 1391, 1394, "IOP", "", 
94023, Peak_IOP, 1493, 1518, "IOP from baseline at peak", "", 
27, Mean, 1629, 1633, "Mean", "", "<http://ctro/data#Mean_100175> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#Mean>. <http://ctro/data#Endpoint_100173> <http://ctro/data#hasAggregationMethod> <http://ctro/data#Mean_100175>."
28, IOP, 1668, 1671, "IOP", "", "<http://ctro/data#IOP_100174> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#IOP>. <http://ctro/data#Endpoint_100173> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#IOP_100174>."
29, BaseLineValue, 1728, 1734, "21 . 3", "", "<http://ctro/data#Outcome_100232> <http://ctro/data#hasBaselineValue> \"21 . 3\". <http://ctro/data#Outcome_100259> <http://ctro/data#hasBaselineValue> \"21 . 3\". <http://ctro/data#Outcome_100358> <http://ctro/data#hasBaselineValue> \"21 . 3\". <http://ctro/data#Outcome_100385> <http://ctro/data#hasBaselineValue> \"21 . 3\"."
30, mmHg, 1735, 1740, "mm Hg", "", "<http://ctro/data#Endpoint_100173> <http://ctro/data#hasBaselineUnit> <http://ctro/data#mmHg>."
68, TimePoint, 1751, 1758, "1 month", "", "<http://ctro/data#Outcome_100232> <http://ctro/data#hasTimePoint> \"1 month\". <http://ctro/data#Outcome_100259> <http://ctro/data#hasTimePoint> \"1 month\"."
84, Brimonidine, 1783, 1794, "brimonidine", "", 
85, Latanoprost, 1799, 1810, "latanoprost", "", 
31, IOP, 1831, 1834, "IOP", "", 
32, Reduction, 1846, 1852, "4 . 88", "", "<http://ctro/data#Outcome_100232> <http://ctro/data#hasChangeValue> \"4 . 88\"."
33, mmHg, 1853, 1857, "mmHg", "", 
34, RelativeReduction, 1860, 1866, "22 . 8", "", "<http://ctro/data#Outcome_100232> <http://ctro/data#hasRelativeChangeValue> \"22 . 8\"."
86, Brimonidine, 1876, 1887, "brimonidine", "", 
35, Reduction, 1892, 1898, "5 . 01", "", "<http://ctro/data#Outcome_100259> <http://ctro/data#hasChangeValue> \"5 . 01\"."
36, mmHg, 1899, 1903, "mmHg", "", 
37, RelativeReduction, 1906, 1912, "23 . 5", "", "<http://ctro/data#Outcome_100259> <http://ctro/data#hasRelativeChangeValue> \"23 . 5\"."
87, Latanoprost, 1922, 1933, "latanoprost", "", 
186, PvalueDiff, 1938, 1947, "= 0 . 798", "", "<http://ctro/data#DiffBetweenGroups_100286> <http://ctro/data#hasPvalueDiff> \"= 0 . 798\"."
40, NumberAffected, 2002, 2004, "44", "", "<http://ctro/data#Outcome_100295> <http://ctro/data#hasNumberAffected> \"44\"."
88, NumberPatientsArm, 2008, 2010, "54", "", "<http://ctro/data#Arm_100188> <http://ctro/data#hasNumberPatientsArm> \"54\"."
89, Brimonidine, 2011, 2022, "brimonidine", "", 
41, NumberAffected, 2036, 2038, "43", "", "<http://ctro/data#Outcome_100322> <http://ctro/data#hasNumberAffected> \"43\"."
90, NumberPatientsArm, 2042, 2044, "53", "", "<http://ctro/data#Arm_100197> <http://ctro/data#hasNumberPatientsArm> \"53\"."
91, Latanoprost, 2045, 2056, "latanoprost", "", 
92, EndPointDescription, 2095, 2121, "15 % IOP reduction at peak", "", "<http://ctro/data#EndPointDescription_100179> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#EndPointDescription>. <http://ctro/data#Endpoint_100178> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#EndPointDescription_100179>."
39, TimePoint, 2137, 2144, "month 1", "", "<http://ctro/data#Outcome_100295> <http://ctro/data#hasTimePoint> \"month 1\". <http://ctro/data#Outcome_100322> <http://ctro/data#hasTimePoint> \"month 1\"."
196, PvalueDiff, 2149, 2158, "= 0 . 963", "", "<http://ctro/data#DiffBetweenGroups_100349> <http://ctro/data#hasPvalueDiff> \"= 0 . 963\"."
197, TimePoint, 2201, 2208, "month 1", "", 
44, Mean, 2257, 2261, "mean", "", 
45, IOP, 2262, 2265, "IOP", "", 
46, Reduction, 2282, 2288, "4 . 55", "", "<http://ctro/data#Outcome_100358> <http://ctro/data#hasChangeValue> \"4 . 55\"."
47, mmHg, 2289, 2293, "mmHg", "", 
94, Brimonidine, 2299, 2310, "brimonidine", "", 
48, Reduction, 2315, 2321, "5 . 49", "", "<http://ctro/data#Outcome_100385> <http://ctro/data#hasChangeValue> \"5 . 49\"."
49, mmHg, 2322, 2326, "mmHg", "", 
95, Latanoprost, 2332, 2343, "latanoprost", "", 
207, PvalueDiff, 2348, 2357, "= 0 . 149", "", "<http://ctro/data#DiffBetweenGroups_100412> <http://ctro/data#hasPvalueDiff> \"= 0 . 149\"."
51, TimePoint, 2363, 2370, "month 3", "", "<http://ctro/data#Outcome_100358> <http://ctro/data#hasTimePoint> \"month 3\". <http://ctro/data#Outcome_100385> <http://ctro/data#hasTimePoint> \"month 3\"."
96, Brimonidine, 2427, 2438, "brimonidine", "", 
97, Latanoprost, 2443, 2454, "latanoprost", "", 
104, EndPointDescription, 2467, 2523, "at least a 15 % additional reduction in IOP for 3 months", "", 
53, IOP, 2507, 2510, "IOP", "", 
98, Duration, 2515, 2523, "3 months", "", 
54, NumberAffected, 2526, 2528, "28", "", "<http://ctro/data#Outcome_100430> <http://ctro/data#hasNumberAffected> \"28\"."
94032, NumberPatientsArm, 2532, 2534, "38", "", 
99, Brimonidine, 2547, 2558, "brimonidine", "", 
55, NumberAffected, 2564, 2566, "30", "", "<http://ctro/data#Outcome_100457> <http://ctro/data#hasNumberAffected> \"30\"."
94033, NumberPatientsArm, 2570, 2572, "36", "", 
100, Latanoprost, 2585, 2596, "latanoprost", "", 
101, EndPointDescription, 2606, 2631, "> or = 15 % IOP reduction", "", 
103, TimePoint, 2635, 2642, "month 3", "", "<http://ctro/data#Outcome_100430> <http://ctro/data#hasTimePoint> \"month 3\". <http://ctro/data#Outcome_100457> <http://ctro/data#hasTimePoint> \"month 3\"."
221, PvalueDiff, 2647, 2656, "= 0 . 314", "", "<http://ctro/data#DiffBetweenGroups_100421> <http://ctro/data#hasPvalueDiff> \"= 0 . 314\"."
105, Latanoprost, 2677, 2688, "latanoprost", "", 
106, Brimonidine, 2782, 2793, "brimonidine", "", 
107, Latanoprost, 2821, 2832, "latanoprost", "", 
94034, EndPointDescription, 2851, 2871, "watery or teary eyes", "", "<http://ctro/data#EndPointDescription_100184> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#EndPointDescription>. <http://ctro/data#Endpoint_100183> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#EndPointDescription_100184>."
56, NumberAffected, 2874, 2876, "34", "", "<http://ctro/data#Outcome_100511> <http://ctro/data#hasNumberAffected> \"34\"."
109, NumberPatientsArm, 2880, 2882, "53", "", 
58, PercentageAffected, 2885, 2891, "64 . 2", "", "<http://ctro/data#Outcome_100511> <http://ctro/data#hasPercentageAffected> \"64 . 2\"."
57, NumberAffected, 2899, 2901, "23", "", "<http://ctro/data#Outcome_100484> <http://ctro/data#hasNumberAffected> \"23\"."
110, NumberPatientsArm, 2905, 2907, "54", "", 
59, PercentageAffected, 2910, 2916, "42 . 6", "", "<http://ctro/data#Outcome_100484> <http://ctro/data#hasPercentageAffected> \"42 . 6\"."
111, Brimonidine, 2924, 2935, "brimonidine", "", 
236, PvalueDiff, 2940, 2949, "= 0 . 025", "", "<http://ctro/data#DiffBetweenGroups_100538> <http://ctro/data#hasPvalueDiff> \"= 0 . 025\"."
106400, EndPointDescription, 2956, 2994, "hands and feet that became cold easily", "", "<http://ctro/data#EndPointDescription_100548> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#EndPointDescription>. <http://ctro/data#Endpoint_100547> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#EndPointDescription_100548>."
61, NumberAffected, 2997, 2999, "24", "", "<http://ctro/data#Outcome_100579> <http://ctro/data#hasNumberAffected> \"24\"."
113, NumberPatientsArm, 3003, 3005, "53", "", 
62, PercentageAffected, 3008, 3014, "45 . 3", "", "<http://ctro/data#Outcome_100579> <http://ctro/data#hasPercentageAffected> \"45 . 3\"."
63, NumberAffected, 3022, 3024, "12", "", "<http://ctro/data#Outcome_100552> <http://ctro/data#hasNumberAffected> \"12\"."
114, NumberPatientsArm, 3028, 3030, "54", "", 
64, PercentageAffected, 3033, 3039, "22 . 2", "", "<http://ctro/data#Outcome_100552> <http://ctro/data#hasPercentageAffected> \"22 . 2\"."
115, Brimonidine, 3047, 3058, "brimonidine", "", 
245, PvalueDiff, 3063, 3072, "= 0 . 012", "", "<http://ctro/data#DiffBetweenGroups_100606> <http://ctro/data#hasPvalueDiff> \"= 0 . 012\"."
66, ConclusionComment, 3091, 3330, "As adjunct therapy with beta - blockers , brimonidine twice daily and latanoprost every day were comparable in lowering IOP at peak effect , but brimonidine was better tolerated , with fewer reports of adverse quality - of - life effects .", "", "<http://ctro/data#ClinicalTrial_100142> <http://ctro/data#hasConclusionComment> \"As adjunct therapy with beta - blockers , brimonidine twice daily and latanoprost every day were comparable in lowering IOP at peak effect , but brimonidine was better tolerated , with fewer reports of adverse quality - of - life effects .\"."
116, Brimonidine, 3133, 3144, "brimonidine", "", 
117, Frequency, 3145, 3156, "twice daily", "", 
118, Latanoprost, 3161, 3172, "latanoprost", "", 
119, Frequency, 3173, 3182, "every day", "", 
120, Peak_IOP, 3211, 3222, "IOP at peak", "", 
121, Brimonidine, 3236, 3247, "brimonidine", "", 
122, PMID, 3338, 3346, "11825814", "", "<http://ctro/data#Publication_100134> <http://ctro/data#hasPMID> \"11825814\"."
